BioWorld

Feb. 21, 2002

IDEC Gains Zevalin Approval For Non-Hodgkin’s Lymphoma

IDEC Pharmaceuticals Corp. received FDA approval of Zevalin to treat non-Hodgkin’s lymphoma and is poised to introduce the first radioimmunotherapy to the United States. (BioWorld Today) Read More

Fresh From Mergers, Buyouts, CEOs Mull Boons And Pitfalls

Pseudomonas aeruginosa, Lethal Cystic Fibrosis Scourge, Trades Surprise Blows With Scientists

Avant Dropping TP10 Following Phase II Failure; Stock Tumbles

Other News To Note

Bush Might Have Final Say On Biotech’s Role In Bioterrorism

Anadys, Structural GenomiX Form Antibacterials Alliance

Today's news in brief

BioWorld

BioWorld briefs for July 17, 2026.

Celia trial: data strong, analysts skeptical

BioWorld

Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 14, 2026

Voyager’s gene therapy reduces tau levels in AD models

BioWorld Science

At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...

Illustration of T cells attacking cancer

GABA signaling linked to immune resistance in some tumors

BioWorld

Certain cancers that contain organized clusters of immune cells known as tertiary lymphoid structures (TLS) do not respond to treatment as well as expected. Even...